NewLeaf Symbiotics

NewLeaf Symbiotics was formed to develop and commercialize one of the most prevalent, beneficial bacteria found in nature: PPFMs (Pink Pigmented Facultative Methylotrophs). NewLeaf Symbiotics is the exclusive licensee of a number of patents on the use of this family of bacteria. NewLeaf Symbiotics has also filed its own related patents, and is actively developing new technologies related to PPFMs. The Company is engaged in laboratory, greenhouse, and field product trials.
Company Growth (employees)
St. Louis, US
Size (employees)
30 (est)+4%
NewLeaf Symbiotics was founded in 1999 and is headquartered in St. Louis, US

Key People/Management at NewLeaf Symbiotics

Thomas Laurita

Thomas Laurita

President and CEO
Stephen Kahn

Stephen Kahn

Senior VP and CFO
Gregg Bogosian

Gregg Bogosian

Chief Scientist
Marcus Jones

Marcus Jones

Vice President, Product Development
Jim Budzynski

Jim Budzynski

VP Business Development and CTO

NewLeaf Symbiotics Office Locations

NewLeaf Symbiotics has an office in St. Louis
St. Louis, US (HQ)
1005 North Warson Road
Show all (1)

NewLeaf Symbiotics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$57.6 m

Latest funding size

$6 m

Time since last funding

6 months


NewLeaf Symbiotics's latest funding round in September 2017 was reported to be $6 m. In total, NewLeaf Symbiotics has raised $57.6 m

NewLeaf Symbiotics's Web-traffic and Trends

NewLeaf Symbiotics News and Updates

NewLeaf Symbiotics nabs $24 mln Series C

St. Louis, Missouri-based NewLeaf Symbiotics, an agricultural biotech company, has secured $24 million in Series C financing. Monsanto Growth Ventures and Otter Capital led the round with participation from other backers that included Lewis & Clark Ventures, Rockport Capital, Pangaea Ventures an…

NewLeaf Symbiotics Company Life and Culture

You may also be interested in